The human epidermal growth factor receptor (HER) family plays an important role in cell survival and proliferation, and is implicated in oncogenesis. Overexpression of HER2 is associated with aggressive disease and poor prognosis. Trastuzumab is a humanized monoclonal antibody targeting HER2 and has proven survival benefit for women with HER2-positive early and metastatic breast cancer. Pertuzumab, another monoclonal antibody, is a HER2 dimerization inhibitor that binds to a different epitope on HER2 than trastuzumab and inhibits HER2 dimer formation with other HER family members such as HER3 and HER1. We investigated the antitumor activity of these agents alone and in combination in HER2-positive breast and non-small cell lung cancer xenografts. Our data show that the combination of trastuzumab and pertuzumab has a strongly enhanced antitumor effect and induces tumor regression in both xenograft models, something that cannot be achieved by either monotherapy. The enhanced efficacy of the combination was also observed after tumor progression during trastuzumab monotherapy. Near-IR fluorescence imaging experiments confirm that pertuzumab binding to tumors is not impaired by trastuzumab pretreatment. Furthermore, we show by in vitro assay that both trastuzumab and pertuzumab potently activate antibody-dependent cellular cytotoxicity. However, our data suggest that the strongly enhanced antitumor activity is mainly due to the differing but complementary mechanisms of action of trastuzumab and pertuzumab, namely inhibition of HER2 dimerization and prevention of p95HER2 formation. [Cancer Res 2009;69(24):9330-6] 
Introduction
The human epidermal growth factor receptor (HER) family comprises HER1, HER2, HER3, and HER4. These proteins are capable of forming heterodimers and homodimers, which activate signal transduction pathways that regulate many cellular processes, including growth, proliferation, and survival (1) . As such, the HER proteins have been implicated in oncogenesis (2) ; in particular, tumors that overexpress the HER2 protein or have amplification of the HER2 gene are associated with aggressive disease and poor prognosis (3) (4) (5) (6) . HER2 overexpression has been identified in numerous tumor types, including 20% to 25% of breast cancers (7) (8) (9) (10) , 4% to 6% of non-small cell lung cancers (NSCLC; refs. 3, 11) , and 20% to 24% of gastric cancers (5, 12) .
Trastuzumab (Herceptin) is a humanized monoclonal antibody that binds to the extracellular domain of HER2, inhibiting HER2-mediated proliferation by activating antibody-dependent cellular cytotoxicity (ADCC; refs. 13, 14) , preventing formation of p95HER2 (a truncated and constitutively active form of HER2; ref. 15) , blocking ligand-independent HER2 signaling (16) , and inhibiting HER2-mediated angiogenesis (17) . Trastuzumab has a proven survival benefit for women with HER2-positive breast cancer both in advanced metastatic disease and in early disease when administered for 1 year as adjuvant therapy (18) (19) (20) (21) (22) . A number of phase II clinical trials have also been carried out in patients with HER2-positive NSCLC with some success, although the number of patients in these trials has been small (23) (24) (25) .
Pertuzumab, a humanized monoclonal antibody, is the first in a new class of HER2 dimerization inhibitors that block HER2 dimerization with other HER family members, thus inhibiting the downstream signaling processes that are associated with tumor growth and progression (26) (27) (28) . Trastuzumab and pertuzumab bind to distinct epitopes on the HER2 extracellular domain, and it has been hypothesized that a combination of the two agents might provide a more effective inhibition of tumor growth than either agent alone (27, 29) . Initial in vitro data suggest that this hypothesis is correct, although in vivo data have been lacking (30) . The aim of this study was to investigate the antitumor effect of the combination of trastuzumab and pertuzumab in HER2-overexpressing NSCLC (Calu-3) and breast cancer (KPL-4) xenograft models.
Materials and Methods
Cell lines and culture. Calu-3 cells were obtained from Chugai Pharmaceuticals Co., Ltd. KPL-4 cells were provided by Professor J. Kurebayashi (Kawasaki Medical School, Kurashiki, Japan). The cells were cultured as previously described (31) .
Tumor xenografts. To initiate tumor xenografts, 5 × 10 6 Calu-3 cells were injected s.c. into BALB/c nu/nu female mice and 3 × 10 6 KPL-4 cells were implanted orthotopically into the right penultimate inguinal mammary fat pad of female severe combined immunodeficient (SCID) beige mice. Tumors were allowed to establish growth (21 d for Calu-3 and 20 d for KPL-4) after implantation before initiation of treatment.
Treatment of animals. Calu-3 or KPL-4 tumors (100 mm 3 ) were treated with trastuzumab (30 mg/kg loading dose, then 15 mg/kg weekly), pertuzumab (30 mg/kg loading dose, then 15 mg/kg weekly), or both, administered i.p. for the duration of the study. Tumor volumes and body weights were measured twice weekly. For the acute study, advanced Calu-3 tumors of ∼400 mm 3 were treated once with trastuzumab and/or pertuzumab at a dose of 30 mg/kg. Samples were harvested 7 d later for immunohistochemistry (IHC) and Western blot analysis. Western blot analysis. For Western blot analysis, protein lysates (20 μg protein/lane) were electrophoresed on TRIS NuPage Ready-Gel (1.0 mm; Invitrogen) for 1 h at 60 V, transferred to nitrocellulose membrane (Hybond enhanced chemiluminescence, Amersham) and incubated with a polyclonal rabbit anti-human c-erbB2 antibody (Dako) at 1 μg/mL. HER2 protein was detected using a labeled secondary antibody diluted at 1:5,000 (goat antirabbit POD labeled; Bio-Rad Laboratories GmbH) and Lumi-Light Western Blotting Substrate (Roche Diagnostics GmbH). The Odyssey detection system (LI-COR Bioscience) was used for quantification.
For control of siRNA experiments (Fig. 5) , 60 μg protein/lane was electrophoresed and blotted onto a polyvinylidene difluoride membrane (Invitrogen). Polyclonal rabbit anti-human ErbB-3 antibody (C-17, sc-285, Santa Cruz) at 1 μg/mL and polyclonal rabbit anti-human epidermal growth factor receptor (EGFR) antibody (06-847, Upstate) at 1 μg/mL were used. Anti-rabbit IgG-HRP-linked antibody (7074, Cell Signaling) was used as secondary antibody at 1:2,000 dilution. Luminescence was detected with Lumi-Light Western Blotting Substrate on the LumiImager Instrument (Roche Diagnostics GmbH).
Assessment of metastases by quantification of human DNA. Genomic DNA was isolated using the High Pure PCR Template Preparation kit (Roche Diagnostics GmbH) and quantified using the PicoGreen Quantification kit (Molecular Probes). Primers for human Alu repeats were synthesized by TIB MOLBIOL GmbH and quantitative PCR (qPCR) was performed using the LightCycler System (Roche Diagnostics GmbH), as previously described (32) .
Near IR fluorescence imaging in vivo. Trastuzumab and pertuzumab were labeled with the fluorescent dye Cy5 (General Electric) according to the manufacturer's instructions. The labeling ratio was 5:1 (Cy5/antibody). When KPL-4 tumors reached a volume of 200 mm 3 , mice were injected i.v. with a single 50-μg dose of either trastuzumab-Cy5 or pertuzumab-Cy5. Near IR fluorescence (NIRF) measurements were performed using the Bon-SAI Imaging System (Siemens Medizintechnik) equipped with an inhalation mask for anesthesia. Fluorescence acquisition time was 4 s for all experiments. For the evaluation of binding competition, mice were injected i.v. with a single dose of trastuzumab (30 mg/kg). After 48 h, Cy5-labeled trastuzumab or pertuzumab (50 μg/mouse) was injected i.v. NIRF signals were measured as described above. ADCC assays. Twenty-four hours before the assay, effector cells [peripheral blood mononuclear cells (PBMC)] were prepared from a healthy blood donor by Ficoll gradient centrifugation. PBMCs were diluted to a final concentration of 2.5 × 10 6 cells/mL in RPMI/10% fetal bovine serum (FBS) and cultured overnight. The following day, the target KPL-4 and Calu-3 cells grown in RPMI/10% FBS were detached using Accutase (PAA Laboratories), sedimented by centrifugation, and resuspended in RPMI/10% FBS at a final concentration of 1 × 10 6 cells/mL. Cells were labeled by adding 1 μL bis (acetoxymethyl) 2,2: 6,2-terpyridine-6,6-dicarboxylic acid (Perkin-Elmer LAS GmbH) per milliliter cell suspension, mixing carefully and incubating for 25 min at 37°C and 5% CO 2 . Cells were washed thrice with 10 mL cell culture medium and diluted to 1.0 × 10 5 cells/mL. To perform the assay, 50 μL of serial dilutions of either trastuzumab or pertuzumab was added to each well of a 96-well plate (Greiner Bio-One GmbH). To test the combination of trastuzumab and pertuzumab, 25 μL of each antibody were added instead. Thus, the final total concentration of the antibody mixture was the same as in the single antibody experiments. Fifty microliters of target cells and PBMCs were added, resulting in a final antibody concentration that ranged from 0.4 to 50 ng/mL and an effector/target ratio of 25:1. Controls included effector cells alone, only target cells and effector cells, and target cells with 3% Triton X-100. Plates were incubated for 2 h at 37°C and 5% CO 2 , and centrifuged at 200× g for 5 min, then 20 μL of each supernatant was transferred into an OptiPlate-96 F (Perkin-Elmer LAS GmbH). After addition of 200 μL Europium solution (Perkin-Elmer LAS GmbH) to each well, the plates were incubated for 15 min on a shaker. Fluorescence was measured using the Victor2 plate reader (Perkin-Elmer LAS GmbH) according to the Eu-TDA protocol (excitation, 340 nm; emission, 615 nm; delay, 400 μs). The percentage of specific release was determined using the following formula: (experimental release − spontaneous release)/(maximum release − spontaneous release) ×100.
siRNA experiments. Calu-3 cells were cultured in RPMI 1640 (Invitrogen) and KPL-4 cells were grown in DMEM (Invitrogen), both were supplemented with 10% FBS. Cells were transfected according to the DharmaFECT 2 reverse transfection protocol (Dharmacon). siRNAs for HER3 and EGFR were purchased from Dharmacon and used at a concentration of 50 nmol/L per well. siRNAs against Eg5 and luciferase were used as positive and negative controls, respectively.
For checking cell proliferation, 1 × 10 4 cells were seeded in normal (Calu-3) or polyhema-coated (KPL-4) 96-well microtiter plates. After 4 d, cells were incubated with CellTiter-Glo reagent (Promega). Luminescence was measured in a Tecan Reader (Tecan Deutschland GmbH). Mocktreated cells were taken as 100%.
For Western blot and reverse transcription-PCR (RT-PCR), 1 × 10 6 cells were seeded in normal (Calu-3) or polyhema-coated 6-well microtiter plates.
For quantitative real-time PCR, cells were harvested at 24 h after transfection. RNA was isolated using an RNeasy Mini kit (Qiagen) with on-column DNase treatment. First-Strand cDNA was produced with Transcriptor First-Strand cDNA Synthesis kit (Roche Diagnostics GmbH). Primers and probes were designed with the Universal Probe Library Assay design center (Roche Diagnostics GmbH). Quantitative RT-PCR was performed using LightCycler 480 Probes Master in duplex PCR with the recommended housekeeping genes (UPL #50 with β-actin for EGFR, UPL #37 with hypoxanthine phosphoribosyltransferase for HER3) on a LightCycler 480 II System (Roche Diagnostics GmbH).
Cells for Western blot analysis were harvested at 48 h after transfection. Statistical analyses. Statistical analyses were performed using SAS software version 8.1 (SAS, Inc.) and the TUMGRO module according to Fieller (33) , and Munzel and Hothorn (34) . Relative tumor growth inhibition was calculated according to the formula (1−[(T−T 0 )/(C−C 0 )]) × 100.
Results

Antitumor Activity of Trastuzumab and Pertuzumab Both Alone and in Combination
Trastuzumab in combination with pertuzumab has strongly enhanced antitumor activity. We investigated the efficacy of trastuzumab and pertuzumab in Calu-3 and KPL-4 tumor xenografts. Mice were treated with either: vehicle control, pertuzumab or trastuzumab alone, or trastuzumab and pertuzumab in combination. In Calu-3 NSCLC xenografts, monotherapy with pertuzumab or trastuzumab was able to significantly inhibit tumor growth, with treatment-to-control ratios (TCR) of 0.23 and 0.27, respectively. The combination of trastuzumab and pertuzumab produced a dramatically enhanced antitumor activity compared with single-agent treatments (TCR 0.05; Table 1 ; Fig. 1A ], resulting in tumor regression and, in 3 of 10 animals, complete tumor remission (Supplementary Fig. S1 ; Table 1 ).
Treatment of KPL-4 breast cancer xenografts with either trastuzumab or pertuzumab inhibited tumor growth with TCRs of 0.67 and 0.65, respectively. Again, combining trastuzumab and pertuzumab induced strongly enhanced antitumor activity compared with either agent alone (TCR 0.04; Table 1 ; Fig. 1B] , resulting in tumor regression and, in 6 of 10 animals, complete tumor remission ( Table 1) .
Combination of trastuzumab and pertuzumab can inhibit metastatic tumor spread. Genomic DNA from lung samples of host animals with KPL-4 xenografts was analyzed by qPCR to investigate if the tumor had metastasized to the lung. Monotherapy with either trastuzumab or pertuzumab did not prevent metastases forming in the lungs of the mice by day 43; however, no human DNA was detected in the lungs of mice treated with the combination of both trastuzumab and pertuzumab, even at day 99, suggesting that this combination completely prevented metastatic tumor spread to the lungs of these animals (Fig. 1C) . Findings for the liver were similar (data not shown). Pertuzumab maintains antitumor activity after progression on trastuzumab. To investigate the combination of trastuzumab and pertuzumab after progression on trastuzumab, SCID mice bearing KPL-4 xenograft tumors were treated with trastuzumab (30 mg/kg loading dose followed by 15 mg/kg weekly) until progression (day 35). At this point, mice either continued treatment with trastuzumab alone or with trastuzumab in combination with pertuzumab. The combination of the two agents was sufficient to inhibit tumor growth and, indeed, reduce tumor mass for a further 45 days (Fig. 1D) . A similar result was obtained using the Calu-3 xenograft model: addition of pertuzumab to continued trastuzumab treatment-induced tumor shrinkage despite progressive growth on trastuzumab single-agent treatment ( Supplementary  Fig. S2 ).
Trastuzumab with pertuzumab induces tumor cell loss. To determine how trastuzumab and pertuzumab were inhibiting tumor growth, an acute study, using just one dose of either trastuzumab and pertuzumab monotherapy or combination therapy, was performed in mice with advanced Calu-3 xenograft tumors. Western blot analysis of HER2 protein levels in tumor lysates showed that both trastuzumab and pertuzumab as single agents reduced HER2 protein levels significantly (TCR, 0.48 and 0.56, respectively). However, combination of trastuzumab with pertuzumab was clearly superior [TCR, 0.17 (confidence interval, 0.00-0.39); Fig. 2A ]. Similar protein decreases were found for HER1, HER3, phosphoHER2, and downstream signaling components (data not shown). A single treatment with combined trastuzumab and pertuzumab resulted in a more than additive effect on the level of HER2 protein ( Fig. 2A) . IHC analysis of tumor tissue confirmed that the reduction in HER2 was due to tumor cell loss and not downregulation of HER2 from the cell surface, as the remaining Calu-3 cells were still HER2 positive (Fig. 2B) . IHC analysis also revealed that the space generated by loss of tumor cells was partially filled by mouse stromal cells, which explains the relative loss of HER2 protein with respect to total protein levels shown by Western blotting (Fig. 2A) .
In vivo visualization of trastuzumab and pertuzumab binding to xenograft tumors. Using NIRF optical imaging, we showed that single-agent trastuzumab-Cy5 and pertuzumab-Cy5 were able to bind to KPL-4 tumors in vivo with equal intensity (Fig. 3A and B,  respectively) . To investigate if trastuzumab and pertuzumab could bind simultaneously to xenograft tumors in vivo, mice were pretreated with unlabeled trastuzumab then with either trastuzumab-Cy5 or pertuzumab-Cy5. Pretreatment with unlabeled trastuzumab inhibited trastuzumab-Cy5 NIRF, indicating receptor saturation (Fig. 3C) . Treatment with pertuzumab-Cy5 resulted in a similar staining intensity as in tumors not pretreated with unlabeled trastuzumab (Fig. 3D) , indicating that binding of pertuzumab is not impaired by trastuzumab. ADCC assays with trastuzumab and/or pertuzumab. To identify the mechanism of action for the strongly enhanced activity of trastuzumab and pertuzumab, we performed in vitro ADCC assays using human PBMCs (effector cells) and either cultured Calu-3 or KPL-4 cells (target cells). Both trastuzumab and pertuzumab applied as single agents effectively activated ADCC against Calu-3 ( Fig. 4A) and KPL-4 cells (Fig. 4B) with equal potency. However, there was no increased ADCC efficiency observed when both agents were used in combination.
HER1, HER2, and HER3 expression in human NSCLC and breast cancer cell lines used for xenograft models and siRNA downregulation of HER1 and HER3. The HER2-positive cell lines KPL-4 and Calu-3 were analyzed for HER-family receptor expression by Western blotting. Whereas Calu-3 showed strong HER1 and moderate HER3 coexpression, KPL-4 cell lysates produced a very strong HER3 and strong HER1 band (see Fig. 5B and D) .
To confirm the HER2 status according to clinical standards, IHC was performed on Calu-3 and KPL-4 xenograft tumors. Both Calu-3 and KPL-4 xenograft tumors were strongly positive for HER2 staining (IHC 3+ using the HercepTest scoring recommendations).
Because HER2 dimerization with either HER1 or HER3 can promote cell survival and proliferation, and act as a potential escape mechanism from trastuzumab inhibition, we performed a knockdown of HER1 and HER3, respectively, and investigated the effect on proliferation of Calu-3 and KPL-4 cells. Calu-3 and KPL-4 cells were transfected with siRNAs targeting either HER1 or HER3, and proliferation was measured. HER1 and HER3 targeting siRNAs effectively downregulated expression of the respective mRNAs roughly by about 60% to 80% in both cell lines (Fig. 5A and C) . Western blot data confirmed that HER1 and HER3 protein expression was effectively reduced after siRNA treatments (Fig. 5B and  D) . In Calu-3 cells, HER1 siRNA treatment inhibited cell growth by ∼30%, whereas downregulation of HER3 reduced growth only by ∼7%, an effect that was no longer statistically significant (Fig. 5A) . Both results on Calu-3 cell growth are consistent with the relative coexpression of HER1 and HER3 in this HER2-positive cell line. In KPL-4 cells, HER3 expression turned out to be more important for cell growth than HER1: whereas HER1-specific siRNA reduced cell growth by ∼10%, HER3 siRNA treatment entailed ∼25% growth inhibition (Fig. 5C) . Again, this result is consistent with the relative coexpression of HER1 and HER3 in the HER2-positive cell line KPL-4.
Discussion
This study has shown that monotherapy with either trastuzumab or pertuzumab has a moderate growth inhibitory effect on NSCLC (Calu-3) and breast (KPL-4) xenograft tumors. The combination treatment with trastuzumab and pertuzumab induced a strongly enhanced antitumor activity in both Calu-3 and KPL-4 xenograft models, resulting in tumor regression and a complete inhibition of metastatic tumor spread in host animals. Moreover, addition of pertuzumab to trastuzumab therapy enhanced antitumor activity in KPL-4 and Calu-3 xenograft tumors that had progressed on trastuzumab. Reduction in the levels of HER2 protein following treatment with trastuzumab and/or pertuzumab was due to a loss of cells expressing HER2 rather than a downregulation of HER2 protein at the cell surface.
The synergistic action of trastuzumab and pertuzumab combination treatment was previously shown in vitro (30) using the calculation of the combination index as outlined by Chou and Talalay (35, 36) . In the present work, combination treatment with trastuzumab and pertuzumab dramatically enhanced the antitumor effect compared with each drug alone: whereas single agent treatments could only delay tumor growth (transiently in KPL-4), the combination treatment induced effective tumor regressions and cures in both xenograft models. We believe that this qualitative difference in antitumor efficacy is a consequence of the synergistic action of both antibodies described in vitro.
In vitro studies investigating the mechanism of action of trastuzumab and pertuzumab have shown that these agents bind to different epitopes on the HER2 protein (27, 37) ; however, concomitant binding to HER2-positive tumors has not been shown in vivo. Using NIRF imaging, we show for the first time that in vivo binding of trastuzumab and pertuzumab is not mutually exclusive. Similar amounts of pertuzumab and trastuzumab, respectively, can bind to HER2-positive tumors when used either in monotherapy or in combination.
Activation of ADCC has been described as a major mechanism of action of trastuzumab (13, 14, 38) and the present study confirms that this is also a property of pertuzumab. Since trastuzumab and pertuzumab are able to bind simultaneously to tumors in vivo, we investigated if the strongly enhanced antitumor effect of these two agents was due to enhanced ADCC. Each antibody alone mediated a strong activation of ADCC, reaching comparable levels of maximal specific target cell lysis. The combination of trastuzumab and pertuzumab (final total antibody concentration identical to those in the single antibody assays) resulted in dose-response curves indistinguishable from those obtained with the single antibodies. Thus, the simultaneous binding of trastuzumab and pertuzumab onto target cells mediates an additive but not synergistic effect on ADCC. The combination of both agents at receptorsaturating concentrations did not enhance this immune effect. This is likely explained by the high receptor density in HER2-overexpressing target cells, which leads to an antibody load that is more than sufficient to elicit the maximum activation of immune effector cells. In this respect, the situation is expected to be similar in vivo because plasma concentrations obtained by therapeutic dosages are above the 20-μg/mL threshold, which ensures HER2 binding saturation with trastuzumab. These data suggest that enhanced ADCC is unlikely to be the mechanism by which the strongly enhanced activity of trastuzumab and pertuzumab, observed in vivo, is mediated. However, as HER2 overexpression is not lost after treatment with either trastuzumab or pertuzumab, ADCC may still provide a mechanism by which both trastuzumab and pertuzumab can continue to provide an antitumor effect even after progression on trastuzumab, as observed in recent clinical trials (39) (40) (41) . These trials and our data suggest that patients who progress on trastuzumab therapy may still benefit from continued trastuzumab and that acquired resistance to trastuzumab is not equivalent to traditional mechanisms of chemotherapy resistance.
The strongly enhanced activity of trastuzumab and pertuzumab is likely attributable to their alternative, differing mechanisms of action. Previous studies have reported that trastuzumab can sterically inhibit access for the proteases that cleave the extracellular domain and, therefore, prevent the formation of p95HER2, the truncated and very active form of HER2 (15, 42) . However, trastuzumab is unable to prevent ligand-activated HER2/HER3 or HER2/HER1 heterodimerization, which may provide tumor cells with an escape mechanism from the inhibitory effects of trastuzumab. In the current study, downregulation of HER3 and HER1 mRNA and protein reduced the proliferation of both Calu-3 and KPL-4 cells. This illustrates the importance of these pathways in the propagation of HER2-positive tumors and they may even become more important when ligand-independent HER2 activation is inhibited by trastuzumab. Pertuzumab prevents the HER2 protein from dimerizing with HER3 and/or HER1 (26, 27, 29, 43) , thus blocking these potential escape pathways. Alternatively, pertuzumab monotherapy can obstruct ligand-activated HER2 dimerization and signaling but would be unable to prevent formation of p95HER2, which is readily achieved by trastuzumab.
Thus, the differing mechanisms of action of trastuzumab and pertuzumab can act in a complementary fashion to provide a more complete blockade of HER2-mediated signal transduction than either agent alone.
In the clinical setting, dramatically enhanced antitumor activity of trastuzumab and pertuzumab has been shown in a phase II clinical trial that investigated the efficacy and safety of a trastuzumab/pertuzumab combination in 66 patients with HER2-positive metastatic breast cancer whose disease had progressed during trastuzumab therapy. Of these patients, 8% had a complete response, with an overall response rate of 24.2% and a clinical benefit rate of 50% (39) . Data from the current study also indicate a potential role for pertuzumab and trastuzumab in HER2-positive NSCLC, although it should be noted that HER2 overexpression is rare in NSCLC.
Conclusions
Trastuzumab and pertuzumab in combination have a strongly enhanced antitumor effect and promote tumor regression in xenograft models of HER2-positive breast cancer and NSCLC. Although both agents potently activate ADCC, this is unlikely to be the main mechanism by which the strongly enhanced effects of this combination are mediated. Instead, the differing but complementary mechanisms of action of trastuzumab and pertuzumab may explain the significantly enhanced antitumor activity produced by combined treatment with these agents. The combination of these agents may prove to be of substantial benefit to patients who currently respond suboptimally to trastuzumab therapy; further trials are warranted.
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